Mirae Asset Global ETFs Holdings’s Travere Therapeutics TVTX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.45M	Buy	49,448 +1,269	+3%	+$37.9K	﹤0.01%	1340
2025 Q4	$1.84M	Buy	48,179 +2,606	+6%	+$84.7K	﹤0.01%	1191
2025 Q3	$1.09M	Sell	45,573 -8,952	-16%	-$168K	﹤0.01%	1438
2025 Q2	$807K	Sell	54,525 -2,252	-4%	-$37.3K	﹤0.01%	1549
2025 Q1	$1.03M	Buy	56,777 +6,831	+14%	+$139K	﹤0.01%	1480
2024 Q4	$869K	Buy	49,946 +9,481	+23%	+$168K	﹤0.01%	1619
2024 Q3	$566K	Sell	40,465 -3,819	-9%	-$39.8K	﹤0.01%	1851
2024 Q2	$364K	Buy	+44,284	New	+$298K	﹤0.01%	1966

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's TVTX Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings increased its Travere Therapeutics (TVTX) stake by 2.6% in Q1 2026, buying an estimated $37.9K and bringing the position to 49,448 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1340.

Mirae Asset Global ETFs Holdings first reported a position in TVTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.84M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Mirae Asset Global ETFs Holdings held 49,448 shares of Travere Therapeutics worth $1.45M as of Q1 2026.
Mirae Asset Global ETFs Holdings bought 1,269 Travere Therapeutics shares in Q1 2026, an estimated $37.9K.
Travere Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #1340 holding.
Mirae Asset Global ETFs Holdings first reported a position in Travere Therapeutics in Q2 2024 and has held it in 8 quarters since.
Mirae Asset Global ETFs Holdings's Travere Therapeutics position peaked at $1.84M in Q4 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.